- Home
- ELAB vs XBIO Comparison
ELAB vs XBIO Comparison
Compare ELAB & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELAB | XBIO |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | 34 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 4.7M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | ELAB | XBIO |
|---|---|---|
| Price | $2.66 | $1.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 37.4K | 22.2K |
| Earning Date | 11-03-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.52 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,976,411.00 |
| Revenue This Year | N/A | $2.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.04 |
| 52 Week Low | $2.59 | $1.85 |
| 52 Week High | $575.40 | $4.94 |
Technical Indicators
Market Signals| Indicator | ELAB | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 23.75 | 32.29 |
| Support Level | $2.59 | N/A |
| Resistance Level | $5.07 | $2.53 |
| Average True Range (ATR) | 0.19 | 0.12 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 5.19 | 11.03 |
Price Performance
Historical ComparisonAbout ELAB Elevai Labs Inc.
PMGC Holdings Inc IS advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.